Boston Trust Walden Corp decreased its stake in Waters Corporation (NYSE:WAT - Free Report) by 2.9% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 95,381 shares of the medical instruments supplier's stock after selling 2,823 shares during the quarter. Boston Trust Walden Corp owned 0.10% of Waters worth $41,909,000 as of its most recent filing with the Securities & Exchange Commission.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Chicago Partners Investment Group LLC lifted its stake in shares of Waters by 8.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 585 shares of the medical instruments supplier's stock valued at $265,000 after purchasing an additional 47 shares during the last quarter. Rakuten Investment Management Inc. boosted its holdings in Waters by 9.7% in the third quarter. Rakuten Investment Management Inc. now owns 17,630 shares of the medical instruments supplier's stock worth $7,815,000 after purchasing an additional 1,562 shares in the last quarter. Provenance Wealth Advisors LLC acquired a new position in Waters during the third quarter worth $50,000. Associated Banc Corp acquired a new stake in shares of Waters in the third quarter worth about $274,000. Finally, Mountain Pacific Investment Advisers LLC raised its stake in shares of Waters by 1.8% in the 3rd quarter. Mountain Pacific Investment Advisers LLC now owns 8,286 shares of the medical instruments supplier's stock valued at $3,641,000 after acquiring an additional 150 shares in the last quarter. 94.01% of the stock is currently owned by hedge funds and other institutional investors.
Waters Stock Up 1.8%
Shares of WAT opened at $467.99 on Thursday. The business's fifty day moving average price is $433.18 and its two-hundred day moving average price is $371.53. The firm has a market capitalization of $45.98 billion, a price-to-earnings ratio of 200.86, a PEG ratio of 2.67 and a beta of 1.16. Waters Corporation has a 52 week low of $282.77 and a 52 week high of $482.28. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.29 and a current ratio of 0.66.
Waters (NYSE:WAT - Get Free Report) last posted its quarterly earnings results on Tuesday, November 3rd. The medical instruments supplier reported $4.10 earnings per share for the quarter, topping analysts' consensus estimates of $4.00 by $0.10. The business had revenue of $1.77 billion during the quarter, compared to the consensus estimate of $1.75 billion. Waters had a net margin of 1.75% and a return on equity of 9.91%. Waters's revenue for the quarter was up 120.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.40 earnings per share. On average, analysts predict that Waters Corporation will post 14.61 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several brokerages have recently issued reports on WAT. Sanford C. Bernstein restated an "outperform" rating and issued a $535.00 price objective on shares of Waters in a research note on Wednesday. Wells Fargo & Company upped their target price on Waters from $370.00 to $400.00 and gave the company an "equal weight" rating in a research note on Wednesday, August 5th. Citigroup raised their target price on Waters from $470.00 to $536.00 and gave the stock a "buy" rating in a research report on Wednesday. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Waters from $400.00 to $440.00 in a research note on Thursday, October 15th. Finally, The Goldman Sachs Group boosted their price target on shares of Waters from $465.00 to $515.00 and gave the company a "buy" rating in a report on Monday, September 21st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, Waters presently has an average rating of "Moderate Buy" and an average price target of $475.48.
Get Our Latest Stock Analysis on Waters
More Waters News
Here are the key news stories impacting Waters this week:
- Positive Sentiment: Q3 results topped expectations. Waters reported adjusted EPS of $4.10 versus about $4.00 expected and revenue of $1.77 billion versus $1.75 billion expected. Organic revenue grew 9% (10% in constant currency); reported revenue growth of 120.9% also reflected acquisitions. Waters Q3 results
- Positive Sentiment: Management raised its 2026 outlook and outlined growth beyond this year. The earnings-call framework pointed to high-single-digit growth and a 29.2% adjusted operating margin for 2027, reinforcing expectations for continued expansion. Earnings call highlights
- Positive Sentiment: Analysts raised targets after the results. Citi raised its target to $536 and kept a Buy rating; TD Cowen and Barclays moved to $530, while RBC set $525. These revisions signal improved confidence in Waters’ prospects. Citi analyst actions
- Positive Sentiment: MOBILion Systems acquisition expands Waters’ proteomics capabilities. Its ion-mobility technology complements Waters’ mass-spectrometry platform and is aimed at research workflows that need faster, higher-resolution data. MOBILion acquisition announcement
- Neutral Sentiment: JPMorgan lifted its price target to $470 but retained a Neutral rating, indicating less near-term upside in its view. JPMorgan analyst action
- Negative Sentiment: Valuation may limit further gains: the supplied market data puts WAT’s P/E at 116.71, and recent commentary has questioned whether the shares already reflect the improved outlook. Waters valuation commentary
Waters Company Profile
(
Free Report)
Waters Corporation NYSE: WAT develops and manufactures analytical technologies used to measure, identify and characterize chemical and biological substances. Its customers include pharmaceutical and biotechnology companies, industrial manufacturers, academic and government laboratories, and organizations involved in food, environmental and clinical testing.
The company's product portfolio includes high-performance liquid chromatography and ultra-performance liquid chromatography systems, mass spectrometers, chromatography columns and consumables, and laboratory software for data management and analysis.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Waters, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.
While Waters currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.